Patents Assigned to LifeArc
  • Patent number: 10961319
    Abstract: The invention provides antibodies and antigen-binding fragments thereof that selectively bind to an epitope within the core region of transglutaminase type 2 (TG2). Novel epitopes within the TG2 core are provided. The invention provides human TG2 inhibitory antibodies and uses thereof, particularly in medicine, for example in the treatment and/or diagnosis of conditions including Celiac disease, scarring, fibrosis-related diseases, neurodegenerative/neurological diseases and cancer.
    Type: Grant
    Filed: May 23, 2018
    Date of Patent: March 30, 2021
    Assignee: LIFEARC
    Inventors: Tim Johnson, Phil Watson, David Matthews, Alex Brown
  • Patent number: 10961233
    Abstract: A first aspect of the invention relates to a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, • B is a saturated or partially unsaturated monocyclic or bicyclic, heterocyclic group optionally substituted by one or more R 10 groups; *X is selected from SO2, CO2, CO, CONR11 and (CR12R13) p. Said compounds are capable of inhibiting PAICS and are useful in the treatment of proliferative disorders. Further aspects relate to pharmaceutical compositions, therapeutic uses and process for preparing compounds of formula (I).
    Type: Grant
    Filed: December 19, 2017
    Date of Patent: March 30, 2021
    Assignee: LIFEARC
    Inventors: Simon Osborne, Jonathan Large
  • Patent number: 10961234
    Abstract: A first aspect of the invention relates to a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein: •B is an aryl or heteroaryl group optionally substituted by one or more R10 groups; and *X is selected from 0, (CR11R12)p and (CR11R12)p CO. Said compounds are capable of inhibiting PAICS and are useful in the treatment of proliferative disorders. Further aspects relate to pharmaceutical compositions, therapeutic uses and process for preparing compounds of formula (I).
    Type: Grant
    Filed: December 19, 2017
    Date of Patent: March 30, 2021
    Assignee: LIFEARC
    Inventors: Simon Osborne, Jonathan Large
  • Patent number: 10918645
    Abstract: Provided are a substituted tricyclic heterocyclic compound of formula I or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt, ester or a prodrug thereof, a pharmaceutical composition including the same and uses thereof. The substituted tricyclic heterocyclic compounds and the pharmaceutical compositions comprising the compounds disclosed herein can be used for treating a disorder caused by at least one of cancer and neurodegenerative diseases. Further the compounds and the pharmaceutical compositions comprising the compounds disclosed herein can be also used for preventing or treating a disorder caused by, associated with or accompanied by any abnormal kinase activity.
    Type: Grant
    Filed: June 13, 2017
    Date of Patent: February 16, 2021
    Assignees: LIFEARC, SUZHOU YABAO PHARMACEUTICAL R&D CO., LTD.
    Inventors: Yan Xia, Edward Giles McIver, Yang Song, Yuanyuan Xu, Lin Zhu, Chunjun Chu, Ling Wu, Miao Liu, Justin Stephen Bryans
  • Publication number: 20200317753
    Abstract: The present invention provides humanized antibodies against Enterovirus 71 (EV71), a causative agent of hand, foot, and mouth disease (HFMD), as well as pharmaceutical compositions comprising these antibodies and methods of their use in the treatment, prophylaxis, and diagnosis of HFMD. These antibodies are suitable for use in human subjects with HFMD or those at risk of HFMD, for example as a result of exposure to infected individuals.
    Type: Application
    Filed: June 2, 2017
    Publication date: October 8, 2020
    Applicant: LifeArc
    Inventors: Tilbe CREIGH-PULATMEN, Seema PATEL, David John MATTHEWS, Zhong HUANG
  • Patent number: 10669284
    Abstract: The present invention relates to compounds of formulae I and H, or pharmaceutically acceptable salts or esters thereof. Further aspects of the invention relate to pharmaceutical compositions and therapeutic uses of said compounds in the treatment of diseases of uncontrolled cell growth, proliferation and/or survival, inappropriate cellular immune responses, inappropriate cellular inflammatory responses, or neurodegenerative disorders, preferably tauopathies, even more preferably, Alzheimer's disease.
    Type: Grant
    Filed: November 16, 2016
    Date of Patent: June 2, 2020
    Assignee: LIFEARC
    Inventors: Jon James Winter-Holt, Edward Giles Mciver, Martin Ambler, Stephen Lewis, Joanne Osborne, Kayleigh Webb-Smith
  • Publication number: 20190307763
    Abstract: Provided are a substituted tricyclic herteocyclic compound of formula I or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt, ester or a prodrug thereof, a pharmaceutical composition including the same and uses thereof. The substituted tricyclic herteocyclic compounds and the pharmaceutical compositions comprising the compounds disclosed herein can be used for treating a disorder caused by at least one of cancer and neurodegenerative diseases. Further the compounds and the pharmaceutical compositions comprising the compounds disclosed herein can be also used for preventing or treating a disorder caused by, associated with or accompanied by any abnormal kinase activity.
    Type: Application
    Filed: June 13, 2017
    Publication date: October 10, 2019
    Applicants: LifeArc, Suzhou Yabao Pharmaceutical R&D Co., Ltd.
    Inventors: Yan XIA, Edward Giles MCIVER, Yang SONG, Yuanyuan XU, Lin ZHU, Chunjun CHU, Ling WU, Miao LIU, Justin Stephen BRYANS
  • Patent number: 10005846
    Abstract: The invention provides antibodies and antigen-binding fragments thereof that selectively bind to an epitope within the core region of transglutaminase type 2 (TG2). Novel epitopes within the TG2 core are provided. The invention provides human TG2 inhibitory antibodies and uses thereof, particularly in medicine, for example in the treatment and/or diagnosis of conditions including Celiac disease, scarring, fibrosis-related diseases, neurodegenerative/neurological diseases and cancer.
    Type: Grant
    Filed: May 24, 2013
    Date of Patent: June 26, 2018
    Assignee: LifeArc
    Inventors: Tim Johnson, Phil Watson, David Matthews, Alex Brown